Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: PRSS35

Gene summary for PRSS35

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

PRSS35

Gene ID

167681

Gene nameserine protease 35
Gene AliasC6orf158
Cytomap6q14.2
Gene Typeprotein-coding
GO ID

GO:0005575

UniProtAcc

Q8N3Z0


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
167681PRSS35ATC13HumanThyroidATC9.49e-852.49e+000.34
167681PRSS35ATC5HumanThyroidATC1.35e-882.64e+000.34
Page: 1 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
PRSS35SNVMissense_Mutationc.988G>Ap.Glu330Lysp.E330KQ8N3Z0protein_codingdeleterious(0)probably_damaging(0.996)TCGA-FI-A2D0-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
PRSS35SNVMissense_Mutationrs375371522c.680C>Tp.Ala227Valp.A227VQ8N3Z0protein_codingtolerated(0.48)benign(0.001)TCGA-FI-A2D5-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinumPD
PRSS35SNVMissense_Mutationnovelc.962T>Gp.Val321Glyp.V321GQ8N3Z0protein_codingdeleterious(0)probably_damaging(0.997)TCGA-FI-A2D5-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinumPD
PRSS35insertionFrame_Shift_Insnovelc.1024_1025insCTCCTCTTp.Glu342AlafsTer16p.E342Afs*16Q8N3Z0protein_codingTCGA-A5-A0R9-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
PRSS35insertionIn_Frame_Insnovelc.637_638insATATTTTGAp.Gly213delinsAspIleLeuSerp.G213delinsDILSQ8N3Z0protein_codingTCGA-B5-A11F-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIHormone TherapymegaceSD
PRSS35insertionFrame_Shift_Insnovelc.637_638insATATTp.Gly213AspfsTer72p.G213Dfs*72Q8N3Z0protein_codingTCGA-B5-A11I-01Endometriumuterine corpus endometrioid carcinomaFemale>=65III/IVChemotherapypaclitaxelPD
PRSS35insertionFrame_Shift_Insnovelc.637_638insATATTp.Gly213AspfsTer72p.G213Dfs*72Q8N3Z0protein_codingTCGA-BG-A0MQ-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
PRSS35insertionIn_Frame_Insnovelc.637_638insATATTTTGAp.Gly213delinsAspIleLeuSerp.G213delinsDILSQ8N3Z0protein_codingTCGA-BS-A0UF-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
PRSS35insertionFrame_Shift_Insnovelc.637_638insATATTp.Gly213AspfsTer72p.G213Dfs*72Q8N3Z0protein_codingTCGA-D1-A0ZP-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapypaclitaxelPD
PRSS35insertionFrame_Shift_Insnovelc.637_638insATATTp.Gly213AspfsTer72p.G213Dfs*72Q8N3Z0protein_codingTCGA-D1-A0ZU-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIChemotherapycarboplatinSD
Page: 1 2 3 4 5 6 7 8 9 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1